Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions

About this update from Sensorion Sas

[{"type":"text","content":"MONTPELLIER, France, May 13, 2025--(BUSINESS WIRE)--Regulatory News:","length":68,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the results of resolutions presented at its Combined General Meeting (CGM), held on May 12, 2025, and made them available on the dedicated section of its website.","length":366,"tagName":"p"},{"type":"text","content":"All resolutions recommended by the Board and submitted to the Combined General Meeting were adopted. 81.7% of the capital was present and represented.","length":150,"tagName":"p"},{"type":"text","content":"The results of the votes on all proposed resolutions can be found on Sensorion's website (https://www.sensorion.com) in the Investors section under the Governance tab.","length":171,"tagName":"p"},{"type":"text","content":"About Sensorion","length":15,"tagName":"p"},{"type":"text","content":"Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.","length":446,"tagName":"p"},{"type":"text","content":"It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.","length":629,"tagName":"p"},{"type":"text","content":"Sensorion’s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevent...

More updates from Sensorion Sas